Other clinical trials targeting EGFR are currently active using different EGFR inhibitors including CM93, a potent EGFR inhibitor with positive results in recurrent GBM with mutant‐EGFR (NCT04933422) [121]; RO7428731 is also in phase I for newly diagnosed and recurrent GBM positive for EGFRvIII (NCT05187624); or ERAS‐801, a CNS‐penetrant EGFR/ERBB1 inhibitor, is in a phase I study for recurrent GBM (NCT05222802). This evidence concerns the gene EGFR and glioblastoma.